We will be pleased to assist you Monday through Thursday from 8 AM to 8 PM ET (with the exception of holidays and certain dates around holidays).
Now, there is a fast and easy way to obtain:
- Samples of JANUVIA
- Access to relevant clinical articles
- Product information from Merck
- Educational materials for your patients
- Answers to clinical questions about JANUVIA
You may speak directly with a Merck representative by calling 1-866-637-2562.
Request More Information
Sign up now and be the first to know about Web site updates, including new clinical studies and interactive tools to support your patients and your practice. Simply enter the following information and click the I AGREE button below.
*Indicates required field
Selected Important Risk Information
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUVIA or with any other antidiabetic drug.
In clinical studies, the adverse reactions reported, regardless of investigator assessment of causality, in 5% of patients treated with JANUVIA as monotherapy and in combination therapy and more commonly than in patients treated with placebo, were upper respiratory tract infection, nasopharyngitis, and headache.
JANUVIA® (sitagliptin) tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.
Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.